Similarly to CLL, in AML the promoter of genes coding for Wnt antagonists (sFRP1, sFRP2, sFRP4, sFRP5, DKK1, and DKK3 etc.)are frequently methylated predicting poor outcome in patients (Jost et al., 2008; Valencia et al., 2009). Here, SFRP4 is linked to B-cell chronic lymphocytic leukemia.